Overview

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if bendamustine can help to control Acute Lymphoblastic Leukemia/Lymphoma (ALL). The safety of this drug will also be studied. Bendamustine is designed to damage and destroy the DNA of cancer cells, which may cause them to die.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Bendamustine Hydrochloride